According to experts at the Serum Institute, the world’s largest vaccine producer, it will take at least until the end of 2024 for everyone in the world to be inoculated with a two-dose COVID-19 vaccine. That adds up to roughly 15.6 billion doses worldwide.
Discovering how to mass produce and distribute the vaccine is perhaps even more crucial than the cure itself. Strand Therapeutics, an MIT biotech spinout based in Cambridge, MA, may have a solution to this bottleneck.
Join us for a riveting conversation with Jacob Becraft, co-founder and CEO of Strand Therapeutics, as he shares his founder’s journey and his progress on developing a delivery platform that can potentially halve the number of COVID-19 vaccine doses required.